Overview Cocaine Use Disorder and Cortical Dopamine Status: Completed Trial end date: 2020-06-01 Target enrollment: Participant gender: Summary The goal of this study is to use [C-11]FLB 457 and amphetamine (oral, 0.5 mg/kg) to measure cortical dopamine transmission in cocaine dependent individuals and healthy controls Phase: Early Phase 1 Details Lead Sponsor: University of PittsburghCollaborator: National Institute on Drug Abuse (NIDA)Treatments: AmphetamineCocaineDextroamphetamineDopamineDopamine AgentsFLB 457